In addition, since TL has the potential to be a predictive biomarker of clinical outcome to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy in patients with Kirsten-ras (KRAS) wild-type metastatic CRC, we aimed to investigate whether KRAS oncogene mutations have an impact on telomere deregulation. The gene discussed is EGFR; the disease is colorectal carcinoma.